Scarica l'app Stockscreener
0.1074
13.05%
0.0124
Dopo l'orario di chiusura:
.10
-0.0074
-6.89%
Precedente Chiudi:
$0.095
Aprire:
$0.1102
Volume 24 ore:
66.19M
Relative Volume:
1.85
Capitalizzazione di mercato:
$14.87M
Reddito:
-
Utile/perdita netta:
$-27.39M
Rapporto P/E:
-0.0639
EPS:
-1.6803
Flusso di cassa netto:
$-2.09M
1 W Prestazione:
+18.02%
1M Prestazione:
+1.03%
6M Prestazione:
-70.62%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.0955
$0.1102
Intervallo di 1 settimana:
$0.0709
$0.1144
Portata 52W:
$0.0709
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Nome
Aspire Biopharma Holdings Inc
Settore
Industria
Telefono
561-704-8527
Indirizzo
23150 FASHION DRIVE, SUITE 232, ESTERO
Confronta ASBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.1074 | 13.15M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aspire Biopharma Holdings Inc Borsa (ASBP) Ultime notizie
Aspire Biopharma Provides Q3 2025 Business Update - The Florida Times-Union
Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching - ts2.tech
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Peoria Journal Star
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance With Continued Listing Requirements - 富途牛牛
Aspire Biopharma Hldgs (ASBP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Aspire Biopharma gets Nasdaq extension to meet listing requirements By Investing.com - Investing.com Nigeria
Aspire Biopharma gets Nasdaq extension to meet listing requirements - Investing.com
POWP ACQUPAR : Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - marketscreener.com
Aspire Biopharma (Nasdaq: ASBP) gains extension, moves to Nasdaq Capital Market - Stock Titan
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Pensacola News Journal
Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback - MSN
Aspire Biopharma Hldgs (ASBPW) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Victorville Daily Press
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Alliance Review
Aspire Biopharma advances sublingual drug delivery technology By Investing.com - Investing.com Nigeria
Aspire Biopharma advances sublingual drug delivery technology - Investing.com
Aspire Biopharma (Nasdaq: ASBP) targets H1 2026 NDA after fast-acting aspirin data - Stock Titan
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Montgomery Advertiser
Aspire Biopharma Holdings Inc Azioni (ASBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):